Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation

Istvan Baczko, David Liknes, Wei Yang, Kevin C. Hamming, Gavin Searle, Kristian Jaeger, Zoltan Husti, Viktor Juhasz, Gergely Klausz, Robert Pap, Laszlo Saghy, Andras Varro, Vernon Dolinsky, Shaohua Wang, Vivek Rauniyar, Dennis Hall, Jason R.B. Dyck, Peter E. Light

Research output: Article

18 Citations (Scopus)


Background and Purpose Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an increased risk for stroke, heart failure and cardiovascular-related mortality. Candidate targets for anti-AF drugs include a potassium channel Kv1.5, and the ionic currents I KACh and late INa, along with increased oxidative stress and activation of NFAT-mediated gene transcription. As pharmacological management of AF is currently suboptimal, we have designed and characterized a multifunctional small molecule, compound 1 (C1), to target these ion channels and pathways. Experimental Approach We made whole-cell patch-clamp recordings of recombinant ion channels, human atrial IKur, rat atrial I KACh, cellular recordings of contractility and calcium transient measurements in tsA201 cells, human atrial samples and rat myocytes. We also used a model of inducible AF in dogs. Key Results C1 inhibited human peak and late Kv1.5 currents, frequency-dependently, with IC50 of 0.36 and 0.11 μmol·L-1 respectively. C1 inhibited I KACh (IC50 of 1.9 μmol·L-1) and the Nav1.5 sodium channel current (IC50s of 3 and 1 μmol·L-1 for peak and late components respectively). C1 (1 μmol·L-1) significantly delayed contractile and calcium dysfunction in rat ventricular myocytes treated with 3 nmol·L -1 sea anemone toxin (ATX-II). C1 weakly inhibited the hERG channel and maintained antioxidant and NFAT-inhibitory properties comparable to the parent molecule, resveratrol. In a model of inducible AF in conscious dogs, C1 (1 mg·kg-1) reduced the average and total AF duration. Conclusion and Implications C1 behaved as a promising multifunctional small molecule targeting a number of key pathways involved in AF.

Original languageEnglish
Pages (from-to)92-106
Number of pages15
JournalBritish journal of pharmacology
Issue number1
Publication statusPublished - jan. 1 2014

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation'. Together they form a unique fingerprint.

  • Cite this

    Baczko, I., Liknes, D., Yang, W., Hamming, K. C., Searle, G., Jaeger, K., Husti, Z., Juhasz, V., Klausz, G., Pap, R., Saghy, L., Varro, A., Dolinsky, V., Wang, S., Rauniyar, V., Hall, D., Dyck, J. R. B., & Light, P. E. (2014). Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation. British journal of pharmacology, 171(1), 92-106.